

ASX Announcement

13 June 2025

Cogstate Launches New Investor Hub

Cogstate Ltd (ASX:CGS) is pleased to announce the launch of its new [InvestorHub](#), designed to provide shareholders with improved access to announcements, company updates, strategic insights, and key information.

From its foundation delivering highly sensitive, standardised digital cognitive assessments, Cogstate is today an essential partner for pharmaceutical and biotech companies worldwide, powering advanced clinical research with evidence-backed technology that delivers unprecedented accuracy and operational efficiency.

Having transitioned to strong revenue, profit and cash growth over the last five years, Cogstate is uniquely positioned at the intersection of increasing investment in R&D in Central Nervous System (CNS) diseases, advanced data analytics, and artificial intelligence.

“As pharmaceutical and biotech companies intensify their focus on neurodegenerative drug development pipelines, Cogstate is poised to capture significant growth opportunities over the next five years and beyond by empowering partners to deliver faster, more reliable, and more innovative clinical research,” said Cogstate CEO Brad O’Connor.

“With Cogstate entering this next exciting phase our new InvestorHub will elevate our engagement with our shareholders and provide a platform to engage actively with new investors.”

Launch of Cogstate Investor Insight Series

Cogstate is today launching its Investor Insight Series via the InvestorHub platform, a series of virtual and in-person events across Australia and the US designed to expand investor reach, elevate the positioning and understanding of Cogstate, and engage a broader investor community.

Please join us at our first event a webinar to showcase the dynamic partnership between Cogstate and Medidata, two leaders in clinical trial technology and cognitive assessment.

Investor participants will gain insights into the transformative impact of this collaboration on CNS disease research and learn how the alliance is accelerating innovation and improving trial outcomes. Featuring Medidata CEO Anthony Costello, the session will highlight Medidata’s industry-leading platform, Cogstate’s expertise in cognitive and clinical assessment, and the combined value they bring to sponsors, researchers, and patients.

Driving Innovation in CNS Trials: The Cogstate-Medidata Partnership and the Future of Central Nervous System Research.

Wednesday, 25 June 2025 at 9:00am AEST (Tuesday, 24 June 2025 at 7:00pm US EST)

Register online for the webinar and InvestorHub via this link: <https://investors.cogstate.com/webinars/7PR1Xr-driving-innovation-in-cns-trials-the-cogstate-medidata-partnership>

View InvestorHub

Cogstate's new InvestorHub will regularly upload new content including videos, key project news and updates. Watch CEO Brad O'Connor's introduction to Cogstate's InvestorHub [here](#).

We invite shareholders and interested [parties to sign up](#) to the InvestorHub and create an account to post questions/feedback to engage with the leadership team and gain a better understanding of the company's updates.

This announcement was authorised for release by Cogstate Ltd CEO, Brad O'Connor.

About Cogstate

Cogstate Ltd (ASX:CGS) is the neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company's clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For over 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world. In the Healthcare market, Cogstate seeks to provide primary care physicians and consumers with brief, accurate and scientifically validated digital measures of cognition, with a focus on easy to use, self-administered tests that inform patients and save physician time. In this market, Cogstate has partnered with pharmaceutical company, Eisai, to distribute Cogstate assessments in Asia. For more information, please visit www.cogstate.com.

For further information contact:

Brad O'Connor, Chief Executive Officer, boconnor@cogstate.com